Kinase

ASSAYQUANT TECHNOLOGIES, INC. EXPANDS PANEL FOR KINOME PROFILING SERVICES

Retrieved on: 
Monday, February 13, 2023
Automation, Kinase, Phosphorylation, DSM-IV codes, Kinetics, HIV disease progression rates, CSO, ATP, Inflammation, Death, FDA, Growth, Cancer, Pharmaceutical industry

MARLBOROUGH, Mass., Feb. 13, 2023 /PRNewswire/ -- AssayQuant Technologies, Inc. today announced that it has expanded its kinome profiling services to include a panel of 400+ unique kinases, including 399 wild-type and 2 mutant enzymes.

Key Points: 
  • MARLBOROUGH, Mass., Feb. 13, 2023 /PRNewswire/ -- AssayQuant Technologies, Inc. today announced that it has expanded its kinome profiling services to include a panel of 400+ unique kinases, including 399 wild-type and 2 mutant enzymes.
  • "We are excited to announce continued expansion of our kinome profiling services," said Dr. Erik Schaefer, AssayQuant's CEO, CSO, and co-founder.
  • By using a continuous assay format for kinome profiling, AssayQuant determines an actual initial reaction rate from dozens of data points in each well.
  • Learn more about AssayQuant Kinome Profiling services: https://resources.assayquant.com/expanded-panel-kinome-profiling

Dense Liquid Droplets Act as Cellular Computers

Retrieved on: 
Wednesday, September 14, 2022
Institute, NMR, Enzyme, American Cancer Society, Ribosome, MAPK3, Crowding, Acceleration, AT8, Department, DAAD, National, Neurodegeneration, NYU Langone Health, Q-system (genetics), Cyclin-dependent kinase 1, Neoplasm, TR01, Computer, European Research Council, Chan Zuckerberg Initiative, The German, Structural biology, National Institutes of Health, Max Planck Society, Biochemistry, MTORC1, Patient, Defense, Genetics, Protein, Cell, German Center for Neurodegenerative Diseases, NYU, Doctor of Philosophy, Research, Water, Kinase, DZNE, New York University Grossman School of Medicine, Alzheimer's disease, Phosphorylation, Phosphorus, Medical imaging, Pharmaceutical industry, Fine chemical, Molecular Cell

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- An emerging field explores how groups of molecules condense together inside cells, the way oil droplets assemble and separate from water in a vinaigrette.

Key Points: 
  • In human cells, "liquid-liquid phase separation" occurs because similar, large molecules glom together into dense droplets separated from the more diluted parts of the fluid cell interior.
  • Researchers compare condensates to microprocessors, computers built into circuits, because both recognize and calculate responses based on incoming information.
  • Kinases are protein switches that influence cellular processes by phosphorylating attaching a molecule called a phosphate group to target molecules.
  • Finally, the researchers also hope that their findings advance the design of other cellular computers that react to physical forces.

Asana BioSciences Announces Dosing of First Patient in Phase 1 Trial of ASN004, a Novel 5T4-Antibody-Drug-Conjugate

Retrieved on: 
Friday, April 8, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Janus, DAR, Principal, Motor neuron, Itch, Cough, Neck, Pharmacokinetics, ADC, Clinical research, Cancer, Monomethyl auristatin F, 5T4, Doctor of Philosophy, Head, Asana, Program, Neoplasm, Janus kinase, Pain, LLC, Safety, JAK3, JAK1, TYK2, ATP, SYK, PI3K, Neuron, JAK, Kinase, Atopic dermatitis, JAK2, Patient, Large-cell lung carcinoma, Respiratory disease, Vaccine, Pharmaceutical industry

ASN004 incorporates a novel single-chain Fv-Fc antibody linked to a clinically validated Auristatin F hydroxypropylamide cytotoxic payload, and drug to antibody ratio (DAR) of approximately 10-12.

Key Points: 
  • ASN004 incorporates a novel single-chain Fv-Fc antibody linked to a clinically validated Auristatin F hydroxypropylamide cytotoxic payload, and drug to antibody ratio (DAR) of approximately 10-12.
  • In preclinical cancer models, a single dose of ASN004 achieved complete and durable tumor regression leading to tumor-free survivors.
  • Asana is focused on discovery and development of novel targeted investigational medicines in immunology/inflammation and oncology.
  • In a Phase 1b study in atopic dermatitis patients, topical application of ASN008 showed rapid onset of pruritus relief (NCT03798561).

Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement

Retrieved on: 
Tuesday, July 6, 2021
Medicine, Clinical medicine, Immunology, Immunometabolism, Metabolism, Health, Cancer, Kinase, Targeted therapy

The IP was developed by the Cancer Research UK Beatson Institute within its Drug Discovery Unit.

Key Points: 
  • The IP was developed by the Cancer Research UK Beatson Institute within its Drug Discovery Unit.
  • The new agreement builds on an existing Material Evaluation and Option Agreement between Sitryx and Cancer Research UK for licensed IP relating to small molecule inhibitors of a target kinase, which plays a critical role in a master regulatory metabolic pathway of emerging importance in immune cells and inflammatory processes.
  • Neil Weir, Chief Executive Officer of Sitryx, said: Through our collaborative discussions with Cancer Research UK, we have identified a critical pathway in the area of immunometabolism.
  • Under the terms of the agreement, Cancer Research UK is eligible to receive development, regulatory and commercial milestones and royalty payments on potential sales from immunometabolism targeted therapeutics developed by Sitryx, with such amounts being invested into Cancer Research UKs life-saving research.

Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Retrieved on: 
Monday, June 28, 2021
Blood, Medical specialties, Hematopathology, Anemias, Transfusion medicine, Haemolytic anaemias, Pyruvate kinase, Hemolysis, Hemolytic anemia, Kinase, Congenital hemolytic anemia, Autoimmune hemolytic anemia

A full analysis of these data including patient-reported outcomes (PRO) was recently presented at theEuropean Hematology Association (EHA) Virtual Congress.

Key Points: 
  • A full analysis of these data including patient-reported outcomes (PRO) was recently presented at theEuropean Hematology Association (EHA) Virtual Congress.
  • An extension study for adults with PK deficiency previously enrolled in ACTIVATE or ACTIVATE-T is ongoing and designed to evaluate the long-term safety, tolerability and efficacy of treatment with mitapivat.
  • Pyruvate kinase (PK) deficiency is a rare, inherited disease that presents as chronic hemolytic anemia, which is the accelerated destruction of red blood cells.
  • The companys most advanced drug candidate is a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that is currently being evaluated for the treatment of three distinct hemolytic anemias.

Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency

Retrieved on: 
Tuesday, June 22, 2021
Blood, Medical specialties, Hematopathology, Branches of biology, Inborn errors of carbohydrate metabolism, Pyruvate kinase, Anemias, Haemolytic anaemias, Hemolysis, Kinase, Hemolytic anemia, Congenital hemolytic anemia

CAMBRIDGE, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced the launch of myAgios patient support services for people living with pyruvate kinase (PK) deficiency and their caregivers.

Key Points: 
  • CAMBRIDGE, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced the launch of myAgios patient support services for people living with pyruvate kinase (PK) deficiency and their caregivers.
  • Pyruvate kinase deficiency is a lifelong hemolytic anemia with no disease-modifying treatments currently available to patients.
  • Patients and caregivers interested in obtaining more detailed content about PK deficiency can enroll in the patient support program at www.myagios.com/patient/pkd-enroll .
  • Pyruvate kinase (PK) deficiency is a rare, inherited disease that presents as chronic hemolytic anemia, which is the accelerated destruction of red blood cells.

Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Retrieved on: 
Monday, June 21, 2021
Blood, Medical specialties, Hematopathology, Hematology, Inborn errors of carbohydrate metabolism, Anemias, Pyruvate kinase, Haemolytic anaemias, Transfusion medicine, Hemolysis, Hemolytic anemia, Kinase

An extension study for adults with PK deficiency previously enrolled in ACTIVATE or ACTIVATE-T is ongoing and designed to evaluate the long-term safety, tolerability and efficacy of treatment with mitapivat.

Key Points: 
  • An extension study for adults with PK deficiency previously enrolled in ACTIVATE or ACTIVATE-T is ongoing and designed to evaluate the long-term safety, tolerability and efficacy of treatment with mitapivat.
  • The company remains on track to submit a marketing authorization application (MAA) in the EU in mid-2021 for mitapivat in adults with PK deficiency.
  • Pyruvate kinase (PK) deficiency is a rare, inherited disease that presents as chronic hemolytic anemia, which is the accelerated destruction of red blood cells.
  • The companys most advanced drug candidate is a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that is currently being evaluated for the treatment of three distinct hemolytic anemias.

Bayer Submits Regulatory Applications for Oncology Treatment Investigational Combination of Aliqopa® (copanlisib) and rituximab in the U.S. and EU

Retrieved on: 
Monday, June 21, 2021
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical trials, Branches of biology, Biology, Oncology, Cell signaling, Programmed cell death, Phosphoinositide 3-kinase, Signal transduction, Kinase, Apoptosis, Phosphoinositide 3-kinase inhibitor, PI3K/AKT/mTOR pathway, Aliqopa® (copanlisib) Injection, non-Hodgkin’s Lymphoma, Oncology at Bayer, Bayer, ALIQOPA® (COPANLISIB) INJECTION, NON-HODGKIN’S LYMPHOMA, ONCOLOGY AT BAYER, BAYER

In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.

Key Points: 
  • In the EU, Bayer has filed for the treatment of relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted.
  • Aliqopa is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K- and PI3K- isoforms expressed in malignant B cells.
  • Aliqopa has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines.
  • The clinical development program for Aliqopa also includes the Phase III study CHRONOS-4, evaluating Aliqopa in combination with standard immunochemotherapy in relapsed iNHL.

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress

Retrieved on: 
Friday, June 11, 2021
Protein kinases, Signal transduction, Ck1, Casein kinase 1, Phosphoinositide 3-kinase, Kinase, PI3

Data from this trial were made available on demand this morning during the 3032 European Hematology Association (EHA) Virtual Congress.

Key Points: 
  • Data from this trial were made available on demand this morning during the 3032 European Hematology Association (EHA) Virtual Congress.
  • UKONIQ is a registered trademark of TG Therapeutics, Inc.
    UKONIQ is the first and onlyoral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon.
  • CK1-epsilonis a regulator of oncoprotein translation and has been implicated in the pathogenesis of cancer cells, including lymphoid malignancies.
  • Monitor for any new or worsening signs and symptoms of infection, including suspected PJP or CMV, during treatment with UKONIQ.

Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress

Retrieved on: 
Friday, June 11, 2021
Branches of biology, Metabolism, Natural sciences, Chemistry, Respiratory physiology, Hemoglobins, Pyruvate kinase, Enzyme, Pyruvic acid, Kinase

Data from the studies will be featured in oral presentations on Tuesday, June 15, at the European Hematology Association (EHA) Virtual Congress.

Key Points: 
  • Data from the studies will be featured in oral presentations on Tuesday, June 15, at the European Hematology Association (EHA) Virtual Congress.
  • Mitapivat is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase R (PKR) enzymes.
  • Mitapivat demonstrated a sustained, statistically significant increase in hemoglobin in patients with PK deficiency who are not regularly transfused.
  • 40 percent (n=16) of patients randomized to mitapivat achieved a hemoglobin response, compared to 0 patients randomized to placebo (2-sided p